Search

Your search keyword '"Daratumumab"' showing total 90 results
Start Over Descriptor "Daratumumab" Journal plus company updates
90 results on '"Daratumumab"'

1. Johnson & Johnson files for U.S. FDA approval of DARZALEX FASPRO(r)-based quadruplet regimen for newly diagnosed multiple myeloma patients for whom transplant is not planned

Subjects
Johnson & Johnson, United States. Food and Drug Administration, Darzalex Faspro (Medication), Drug therapy, Multiple myeloma -- Drug therapy, Daratumumab, Pharmaceutical industry, Drug approval, Stem cell transplantation, Stem cells -- Transplantation
Abstract

RARITAN, N.J: Johnson & Johnson has issued the following news release: Johnson & Johnson (NYSE:JNJ) announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food [...]

Published
2024

2. Karyopharm Announces National Comprehensive Cancer Network(r) Adds Three XPOVIO(r) (selinexor) Treatment Regimens to Its Clinical Practice Guidelines in Oncology for Multiple Myeloma

Subjects
Cancer -- Drug therapy, Pomalidomide, Multiple myeloma -- Drug therapy, Daratumumab, Dexamethasone, General interest, News, opinion and commentary, National Comprehensive Cancer Network, Xpovio (Medication)
Abstract

NEWTON: Karyopharm Therapeutics Inc. has issued the following press release: Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the National Comprehensive Cancer Network(r) [...]

Published
2020

3. Full data set of Oncopeptides phase 2 HORIZON study in multiple myeloma published in the Journal of Clinical Oncology

Subjects
United States. Food and Drug Administration, Pomalidomide, Multiple myeloma -- Care and treatment, Daratumumab, Drug approval, Dexamethasone -- Product development, General interest, News, opinion and commentary
Abstract

STOCKHOLM: Oncopeptides AB has issued the following news release: Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases, today [...]

Published
2020

4. Oncopeptides presents new data from phase 2 ANCHOR combination study in multiple myeloma at American Society of Hematology meeting ASH

Subjects
Professional associations, Multiple myeloma, Daratumumab, Dexamethasone -- Product development, General interest, News, opinion and commentary
Abstract

STOCKHOLM: Oncopeptides AB has issued the following news release: Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases today [...]

Published
2020

5. Amgen Announces New Data Being Presented At ASH 2020

Subjects
Carfilzomib, Blinatumomab, Daratumumab, T cells, General interest, News, opinion and commentary
Abstract

THOUSAND OAKS: Amgen has issued the following news release: Amgen (NASDAQ:AMGN) today announced several upcoming data presentations from its oncology and hematology pipeline and marketed product portfolio at the 62nd [...]

Published
2020

6. Shanghai Henlius Biotech, Inc.: VOLUNTARY ANNOUNCEMENT APPLICATION FOR CLINICAL TRIAL FOR RECOMBINANT ANTI-CD38 HUMAN MONOCLONAL ANTIBODY INJECTION (HLX15) FOR THE TREATMENT OF MULTIPLE MYELOMA ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION (Stock Code: 2696)

Subjects
Clinical trials, Medical supplies -- Product development, B cells, Multiple myeloma, Daratumumab, Securities law, General interest, News, opinion and commentary
Abstract

Hong Kong: Shanghai Henlius Biotech, Inc. has issued the following announcement: This announcement is made by Shanghai Henlius Biotech, Inc. (the 'Company') on a voluntary basis to inform the shareholders [...]

Published
2020

7. Oncopeptides Announces that New Data for Melflufen is Accepted for Presentation at the Annual American Society of Hematology Meeting

Subjects
Professional associations, Carfilzomib, Drug resistance, Daratumumab, General interest, News, opinion and commentary
Abstract

STOCKHOLM: Oncopeptides AB has issued the following news release: Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a pharmaceutical company focusing on the development of targeted therapies for difficult-to-treat hematological diseases, today [...]

Published
2020

8. Actinium Pharmaceuticals, Inc. Expands R&D Capabilities with New Research Facility to Enhance Development of Next Generation Antibody Radiation Conjugates Leveraging Its Proprietary AWE Platform

Subjects
Cells (Biology), Daratumumab, Radiation (Physics), General interest, News, opinion and commentary
Abstract

NEW YORK: Actinium Pharmaceuticals, Inc. has issued the following news release: Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ('Actinium' or the 'Company') today announced the launch of its new research and [...]

Published
2020

9. Ligand Announces Amgen's KYPROLIS(r) Approved by FDA as Combination Regimen with DARZALEX(r) and Dexamethasone in Once- and Twice-Weekly Dosing Regimens for Patients with Relapsed|Refractory Multiple Myeloma

Subjects
United States. Food and Drug Administration, Ligand Pharmaceuticals Inc., Carfilzomib, Recurrence (Disease) -- Drug therapy, Central nervous system depressants, Multiple myeloma -- Drug therapy, Daratumumab, Drug approval, Dexamethasone, General interest, News, opinion and commentary, Darzalex (Medication)
Abstract

SAN DIEGO: Ligand Pharmaceuticals Incorporated has issued the following press release: Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that a major Captisol customer Amgen (NASDAQ: AMGN) has received U.S. Food and [...]

Published
2020

10. GSK receives positive CHMP opinion recommending approval of belantamab mafodotin for the treatment of relapsed and refractory multiple myeloma

Subjects
GlaxoSmithKline PLC, B cells, Pomalidomide, Recurrence (Disease) -- Care and treatment, Multiple myeloma -- Care and treatment, Pembrolizumab, Daratumumab, Pharmaceutical industry, General interest, News, opinion and commentary
Abstract

Brentford: GlaxoSmithKline plc (GSKN.MX) has issued the following press release: GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency [...]

Published
2020

11. Indapta Therapeutics Provides Corporate Update

Subjects
Elotuzumab, Daratumumab, General interest, News, opinion and commentary
Abstract

SAN FRANCISCO: Indapta Therapeutics, Inc. has issued the following news release: Indapta Therapeutics, Inc., a biotechnology company focused on developing and commercializing a proprietary, first-in-class, off-the-shelf, non-engineered, allogeneic FcRg-deficient natural [...]

Published
2020

12. Halozyme Announces Findings From Janssen's Phase 3 Andromeda Study Evaluating Subcutaneous Daratumumab Utilizing ENHANZE(r) In Light-Chain Amyloidosis Presented At European Hematology Association 25th Annual Congress

Subjects
Amyloidosis, Daratumumab, General interest, News, opinion and commentary
Abstract

SAN DIEGO: Halozyme Therapeutics, Inc. has issued the following news release: Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Janssen Research & Development, LLC (Janssen) presented data from its Phase [...]

Published
2020

13. Subcutaneous Daratumumab Combination Resulted in Deep and Rapid Hematologic Responses and Improved Clinical Outcomes in the Treatment of Patients with Newly Diagnosed Light Chain (AL) Amyloidosis

Subjects
Johnson & Johnson, Amyloidosis -- Patient outcomes -- Care and treatment, Daratumumab, Pharmaceutical industry, General interest, News, opinion and commentary
Abstract

RARITAN: The Janssen Pharmaceutical Companies of Johnson & Johnson has issued the following news release: The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the first randomized [...]

Published
2020

14. Halozyme Announces Janssen Receives European Marketing Authorization For Subcutaneous DARZALEX(r) Utilizing Halozyme's ENHANZE(r) Technology For The Treatment Of Patients With Multiple Myeloma

Subjects
Marketing, Multiple myeloma, Daratumumab, Drug approval, Time, Technology, Setting (Literature), General interest, News, opinion and commentary, European Union. European Commission, Darzalex (Medication)
Abstract

SAN DIEGO: Halozyme Therapeutics, Inc. has issued the following press release: Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the European Commission (EC) has granted Janssen-Cilag International NV (Janssen) marketing [...]

Published
2020

15. European Commission Grants Marketing Authorisation for DARZALEX(r)V(daratumumab) Subcutaneous Formulation for all Currently Approved Daratumumab Intravenous Formulation Indications

Subjects
Johnson & Johnson, Hyaluronidase, Marketing, Multiple myeloma, Daratumumab, Pharmaceutical industry, Time, General interest, News, opinion and commentary, European Union. European Commission, Darzalex (Medication)
Abstract

BEERSE: Janssen has issued the following press release: The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) has granted marketing authorisation for DARZALEX(r)V (daratumumab) [...]

Published
2020

16. Oncopeptides Announces New Clinical and Preclinical Melflufen Data at the Upcoming European Hematology Association Meeting

Subjects
Pomalidomide, Multiple myeloma -- Care and treatment, Daratumumab, Associations, Recurrence (Disease), Peptides, Tumors, General interest, News, opinion and commentary
Abstract

STOCKHOLM: Oncopeptides AB has issued the following news release: Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that data from the pivotal phase 2 study HORIZON, and additional clinical and preclinical [...]

Published
2020

17. Halozyme To Receive $15 Million Milestone Payment From Janssen

Subjects
Hyaluronidase -- Licensing agreements, Daratumumab, Drug approval, Biotechnology, Company licensing agreement, General interest, News, opinion and commentary
Abstract

SAN DIEGO: Halozyme Therapeutics, Inc. has issued the following press release: Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the company will receive a $15 million milestone payment from Janssen Biotech, [...]

Published
2020

18. Amgen Showcases Oncology Pipeline At ASCO 2020

Subjects
Pipelines, Ipilimumab, Carfilzomib, Colorectal cancer, Pembrolizumab, Daratumumab, Talimogene laherparepvec, T cells, Acute myelocytic leukemia, Cancer, Myeloid leukemia, Tumors, Marketing, Cancer patients, General interest, News, opinion and commentary
Abstract

THOUSAND OAKS: Amgen has issued the following news release: Amgen (NASDAQ:AMGN) today announced that data from its oncology pipeline and marketed portfolio will be presented during the ASCO20 Virtual Scientific [...]

Published
2020

19. CHMP Grants Positive Opinion for DARZALEX(r)V(daratumumab) Subcutaneous Formulation for the Treatment of Patients with Multiple Myeloma

Subjects
Johnson & Johnson, Drug delivery systems, Hyaluronidase, Multiple myeloma -- Care and treatment, Daratumumab, Pharmaceutical industry, Time, Technology, Setting (Literature), Novels, General interest, News, opinion and commentary, Darzalex (Medication)
Abstract

BEERSE: Janssen has issued the following press release: The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the Committee for Medicinal Products for Human Use (CHMP) of the [...]

Published
2020

20. Halozyme Announces Janssen's Receipt Of CHMP Positive Opinion For DARZALEX(r) Subcutaneous Formulation Utilizing Halozyme's ENHANZE(r) Technology For Patients With Multiple Myeloma

Subjects
Drug delivery systems, Multiple myeloma -- Care and treatment, Daratumumab, Technology, Setting (Literature), General interest, News, opinion and commentary, Darzalex (Medication)
Abstract

SAN DIEGO: Halozyme Therapeutics, Inc. has issued the following news release: Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Janssen-Cilag International NV (Janssen) received a Committee for Medicinal Products for [...]

Published
2020

21. Halozyme Announces Janssen Submits New Drug Application In Japan For Daratumumab Subcutaneous Formulation Utilizing Halozyme's ENHANZE(r) Technology For Patients With Multiple Myeloma

Subjects
Hyaluronidase, Multiple myeloma -- Drug therapy, Daratumumab, Technology, Media executives, Health, General interest, News, opinion and commentary
Abstract

SAN DIEGO: Halozyme Therapeutics, Inc. has issued the following press release: Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the submission of a New Drug Application (NDA) to the Ministry of [...]

Published
2020

22. Oncopeptides provides update regarding COVID-19 impact on the melflufen clinical program

Subjects
Patient care, Medical research, Daratumumab, Oceans, Clinical trials, General interest, News, opinion and commentary
Abstract

Stockholm: Oncopeptides has issued the following press release: Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today measures the company is taking in response to the global spread of the novel coronavirus [...]

Published
2020

23. Genmab Publishes 2019 Annual Report

Subjects
Genmab A/S, Daratumumab, Pharmaceutical industry, Economic forecasting, Ofatumumab, Finance, General interest, News, opinion and commentary, Darzalex (Medication)
Abstract

Copenhagen: Genmab A/S has issued the following press release: Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2019. Below is a summary of business progress [...]

Published
2020

24. Sebia SA Product Pipeline Analysis - 2019 Update

Subjects
Daratumumab, Electrophoresis, Exports, Medical equipment, Backup software, General interest, News, opinion and commentary
Abstract

DUBLIN: Research and Markets has issued the following news release: The 'Sebia SA - Product Pipeline Analysis, 2019 Update' company profile has been added to ResearchAndMarkets.com's offering. Summary Sebia SA [...]

Published
2020

25. Janssen Announces Submission to U.S. FDA for New DARZALEX(r) (Daratumumab)-Based Combination Regimen for Patients with Relapsed|Refractory Multiple Myeloma

Subjects
United States. Food and Drug Administration, Johnson & Johnson, Carfilzomib, Recurrence (Disease) -- Care and treatment, Multiple myeloma -- Care and treatment, Daratumumab, Pharmaceutical industry, Drug approval, Dexamethasone, Glucocorticoids, General interest, News, opinion and commentary, Darzalex (Medication)
Abstract

RARITAN: Janssen Oncology has issued the following press release: The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA) to the [...]

Published
2020

26. Genmab Announces 2019 Net Sales Figures for DARZALEX(r) (daratumumab) and Achievement of USD 150 Million Sales Milestone in DARZALEX Collaboration with Janssen

Subjects
Johnson & Johnson -- Licensing agreements -- Company sales and earnings, Genmab A/S -- Licensing agreements -- Company sales and earnings, Daratumumab, Pharmaceutical industry -- Licensing agreements -- Company sales and earnings, Royalties (Intellectual property), Biotechnology, Company earnings/profit, Company licensing agreement, General interest, News, opinion and commentary, Darzalex (Medication)
Abstract

Copenhagen: Genmab A/S has issued the following press release: Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX(r) (daratumumab) as reported by Johnson & Johnson were [...]

Published
2020

27. European Commission Approves Darzalex(r)V (daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone (VTd) for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible

Subjects
Johnson & Johnson, Bortezomib, Multiple myeloma -- Care and treatment, Daratumumab, Pharmaceutical industry, Drug approval, Thalidomide, Dexamethasone, Stem cell transplantation, Stem cells, Antineoplastic agents, Glucocorticoids, Central nervous system depressants, Marketing, Professional associations, General interest, News, opinion and commentary, European Union. European Commission, Darzalex (Medication)
Abstract

BEERSE, Belgium: Janssen has issued the following news release: The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) has granted marketing authorisation for Darzalex(r) [...]

Published
2020

28. Genmab Announces European Marketing Authorization for DARZALEX(r) (Daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma

Subjects
Genmab A/S, Bortezomib, Marketing, Multiple myeloma, Daratumumab, Pharmaceutical industry, Drug approval, Thalidomide, Dexamethasone, Stem cells, Antineoplastic agents, Glucocorticoids, Biotechnology, Central nervous system depressants, Stem cell transplantation, General interest, News, opinion and commentary, European Union. European Commission, Darzalex (Medication)
Abstract

DENMARK: Genmab A/S has issued the following press release: Genmab A/S (Nasdaq: GMAB) announced today that the European Commission (EC) has granted marketing authorization for DARZALEX(r) (daratumumab) in combination with [...]

Published
2020

29. Halozyme Provides 2020 Business Update And Financial Guidance

Subjects
United States. Food and Drug Administration, Daratumumab, Drug approval, Media executives, General interest, News, opinion and commentary
Abstract

SAN DIEGO: Halozyme Therapeutics, Inc. has issued the following press release: Halozyme Therapeutics, Inc. (NASDAQ: HALO) today provided an update on its outlook for 2020, including financial guidance. 'We have [...]

Published
2020

30. Molecular Templates Provides Corporate Update and Outlines 2020 Milestones

Subjects
Pertuzumab, Daratumumab, Equity (Finance), Therapeutics, Media executives, General interest, News, opinion and commentary
Abstract

AUSTIN: Molecular Templates, Inc. has issued the following press release: Molecular Templates, Inc., (Nasdaq: MTEM) a clinical-stage biopharmaceutical company focused on the discovery and development of the Company's proprietary targeted [...]

Published
2020

31. Multiple Myeloma Update Bulletin #3, 2019 - Presents KOL Views on Recent Developments in the Treatment of Multiple Myeloma

Subjects
Johnson & Johnson, Multiple myeloma -- Drug therapy, Daratumumab, Pharmaceutical industry -- International economic relations, Drug approval, Marketing, General interest, News, opinion and commentary, Darzalex (Medication)
Abstract

Dublin: Research and Markets has issued the following press release: The 'Multiple Myeloma: Update Bulletin # 3' report has been added to ResearchAndMarkets.com's offering. This edition presents key opinion leader [...]

Published
2019

32. CHMP Grants Positive Opinion for Expanded Use of Darzalex(r)V (daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone (VTd) for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible

Subjects
Johnson & Johnson, Bortezomib -- Usage, Multiple myeloma -- Care and treatment, Daratumumab, Pharmaceutical industry, Thalidomide -- Usage, Dexamethasone -- Usage, Stem cell transplantation, Stem cells, Marketing, Antineoplastic agents, Glucocorticoids, Central nervous system depressants, General interest, News, opinion and commentary, Darzalex (Medication)
Abstract

BEERSE: Janssen has issued the following press release: The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the Committee for Medicinal Products for Human Use (CHMP) of the [...]

Published
2019

33. CHMP Issues Positive Opinion Recommending DARZALEX(r) (Daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma

Subjects
Genmab A/S, Bortezomib, Multiple myeloma, Daratumumab, Pharmaceutical industry, Thalidomide, Dexamethasone, Stem cells, Stem cell transplantation, Marketing, Antineoplastic agents, Glucocorticoids, Central nervous system depressants, General interest, News, opinion and commentary, Darzalex (Medication)
Abstract

Copenhagen: Genmab A/S has issued the following press release: Genmab A/S (Nasdaq: GMAB) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency [...]

Published
2019

34. Darzalex(r)V (daratumumab) Regimen Shows Significant Increase in Progression-Free Survival in Treatment of Patients with Relapsed|Refractory Multiple Myeloma (Updated on December 12, 2019)

Subjects
Johnson & Johnson, Carfilzomib, Recurrence (Disease) -- Development and progression -- Patient outcomes -- Care and treatment, Multiple myeloma -- Development and progression -- Patient outcomes -- Care and treatment, Daratumumab, Pharmaceutical industry, Dexamethasone, Death, Glucocorticoids, General interest, News, opinion and commentary, Darzalex (Medication)
Abstract

BEERSE, Belgium: Janssen has issued the following news release: The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the Phase 3 CANDOR study showing that the addition [...]

Published
2019

35. Darzalex(r)V (daratumumab) Shows Overall Survival Benefit and Continued Improvement in Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Who are Ineligible for Transplant (Updated on December 10, 2019)

Subjects
Johnson & Johnson, Multiple myeloma -- Patient outcomes -- Care and treatment, Daratumumab, Pharmaceutical industry, Death, Prednisone, Operating systems (Software), Glucocorticoids, Bortezomib, General interest, News, opinion and commentary, Darzalex (Medication)
Abstract

BEERSE: Janssen has issued the following news release: The Janssen Pharmaceutical Companies of Johnson & Johnson announced today overall survival (OS) results from the Phase 3 ALCYONE study, which showed [...]

Published
2019

36. DARZALEX(r) (Daratumumab) Regimen Shows Significant Increase in Progression-Free Survival in Treatment of Patients with Relapsed|Refractory Multiple Myeloma

Subjects
Johnson & Johnson, Carfilzomib, Recurrence (Disease) -- Development and progression -- Patient outcomes -- Care and treatment, Multiple myeloma -- Development and progression -- Patient outcomes -- Care and treatment, Daratumumab, Pharmaceutical industry, Dexamethasone, Death, Glucocorticoids, Professional associations, General interest, News, opinion and commentary, Darzalex (Medication)
Abstract

ORLANDO: Janssen Oncology has issued the following press release: The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the Phase 3 CANDOR study showing the addition of [...]

Published
2019

37. Darzalex(r)V (daratumumab) Regimen Shows Significant Increase in Progression-Free Survival in Treatment of Patients with Relapsed|Refractory Multiple Myeloma

Subjects
Johnson & Johnson, Carfilzomib, Recurrence (Disease) -- Development and progression -- Patient outcomes -- Care and treatment, Multiple myeloma -- Development and progression -- Patient outcomes -- Care and treatment, Daratumumab, Pharmaceutical industry, Dexamethasone, Death, Glucocorticoids, General interest, News, opinion and commentary, Darzalex (Medication)
Abstract

BEERSE: Janssen has issued the following news release: The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the Phase 3 CANDOR study showing that the addition of [...]

Published
2019

39. Adaptive Biotechnologies and Collaborators to Present Data from More Than 25 clonoSEQ(r) Abstracts at ASH 2019 Demonstrating Clinical Relevance of Standardized, Accurate MRD Testing for Blood Cancer Patients

Subjects
Biotechnology, Ixazomib, Medical tests, Axicabtagene ciloleucel, Daratumumab, Cancer patients, Obinutuzumab, Antineoplastic agents, Lymphocytic leukemia, Bendamustine, Carfilzomib, Venetoclax, Immune system, Backup software, Ibrutinib, Acute lymphocytic leukemia, General interest, News, opinion and commentary
Abstract

Washington: Adaptive Biotechnologies has issued the following press release: Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system [...]

Published
2019

40. Amgen Announces Data Being Presented At ASH 2019

Subjects
Denosumab, Carfilzomib, Blinatumomab, Daratumumab, Inotuzumab ozogamicin, Zoledronic acid, T cells, Dexamethasone, Recurrence (Disease), Glucocorticoids, Professional associations, General interest, News, opinion and commentary, Darzalex (Medication)
Abstract

THOUSAND OAKS: Amgen has issued the following press release: Amgen (NASDAQ:AMGN) today announced new clinical data from its oncology in-line products and pipeline that will be presented at the 61st [...]

Published
2019

41. Janssen Receives EU Marketing Authorisation for Darzalex(r)V(daratumumab) in Combination with Lenalidomide and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible

Subjects
Johnson & Johnson, Angiogenesis inhibitors, Central nervous system depressants, Marketing, Multiple myeloma, Stem cells, Daratumumab, Pharmaceutical industry, Lenalidomide, Dexamethasone, Stem cell transplantation, Recurrence (Disease), Glucocorticoids, Periodicals, General interest, News, opinion and commentary, European Union. European Commission, Darzalex (Medication)
Abstract

BEERSE: Janssen has issued the following press release: The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) has granted marketing authorisation for Darzalex(r)(daratumumab) in [...]

Published
2019

42. Genmab Announces European Marketing Authorization for DARZALEX(r) (Daratumumab) in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma

Subjects
Genmab A/S, Angiogenesis inhibitors, Central nervous system depressants, Marketing, Multiple myeloma, Daratumumab, Pharmaceutical industry, Drug approval, Lenalidomide, Dexamethasone, Stem cell transplantation, Stem cells, Glucocorticoids, Biotechnology, General interest, News, opinion and commentary, European Union. European Commission, Darzalex (Medication)
Abstract

DENMARK: Genmab A/S has issued the following news release: Genmab A/S (Nasdaq: GMAB) announced today that the European Commission (EC) has granted marketing authorization for DARZALEX(r) (daratumumab) in combination with [...]

Published
2019

43. Sorrento to Present New Data on Advanced Immunotherapies at Multiple Upcoming Scientific Conferences

Subjects
Immunotherapy, Daratumumab, Genes, Antigens, Technology, Chairpersons, Production management, General interest, News, opinion and commentary
Abstract

California: Sorrento Therapeutics, Inc. has issued the following news release: Sorrento Therapeutics, Inc. (NASDAQ: SRNE, 'Sorrento'), announced today that Dr. Henry Ji, Chairman and CEO, and members of Sorrento's research [...]

Published
2019

44. Genmab Announces Financial Results for the First Nine Months of 2019

Subjects
Novartis AG -- Company sales and earnings, Genmab A/S -- Company sales and earnings, Daratumumab, Pharmaceutical industry -- Company sales and earnings, Ofatumumab, Stock offerings, Antibodies, Company earnings/profit, General interest, News, opinion and commentary
Abstract

Copenhagen: Genmab A/S has issued the following press release: Genmab made excellent progress across many areas of the business during the third quarter of 2019. Of key significance was the [...]

Published
2019

45. Janssen to Present Latest Research from Robust Blood Cancer and Cardiovascular Disease Portfolios at this Year's American Society of Hematology Annual Meeting

Subjects
Johnson & Johnson, Cancer, Cancer research, Rivaroxaban, Daratumumab, Pharmaceutical industry, Cardiovascular diseases, Antineoplastic agents, Monoclonal antibodies, Automobiles, Phenols (Class of compounds), Carfilzomib, Tyrosine, Venetoclax, Antibodies, Ibrutinib, Corporate sponsorship, General interest, News, opinion and commentary, Imbruvica (Medication), Darzalex (Medication), Xarelto (Medication)
Abstract

RARITAN: The Janssen Pharmaceutical Companies of Johnson & Johnson has issued the following press release: The Janssen Pharmaceutical Companies of Johnson & Johnson announced today 46 company-sponsored and more than [...]

Published
2019

46. bluebird bio to Present New Data from Gene and Cell Therapy Programs at 61st American Society of Hematology Annual Meeting and Exposition

Subjects
bluebird bio, Inc., Celgene Corp., Carfilzomib, Tocilizumab, Pomalidomide, Genes, Biotechnology industries, Multiple myeloma, Daratumumab, Pharmaceutical industry, Sickle cell anemia, T cells, Antigens, Automobiles, Thalassemia, Clinical trials, General interest, News, opinion and commentary
Abstract

CAMBRIDGE: bluebird bio, Inc. has issued the following press release: bluebird bio, Inc. (Nasdaq: BLUE) announced today that new and updated data from its investigational gene and cell therapy programs [...]

Published
2019

47. CHMP Issues Positive Opinion Recommending DARZALEX(r) (Daratumumab) in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma

Subjects
Genmab A/S, Angiogenesis inhibitors, Central nervous system depressants, Multiple myeloma -- Care and treatment, Daratumumab, Pharmaceutical industry, Lenalidomide, Dexamethasone, Stem cells, Stem cell transplantation, Marketing, Glucocorticoids, General interest, News, opinion and commentary, European Union, Darzalex (Medication)
Abstract

Copenhagen: Genmab A/S has issued the following press release: Genmab A/S (Nasdaq: GMAB) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency [...]

Published
2019

48. Genmab Announces U.S. FDA Approval of DARZALEX(r) (daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone for Frontline Multiple Myeloma

Subjects
United States. Food and Drug Administration, Genmab A/S, Bortezomib, Multiple myeloma, Daratumumab, Pharmaceutical industry, Drug approval, Thalidomide, Prescriptions (Drugs), Dexamethasone, Stem cells, Legal fees, Antineoplastic agents, Glucocorticoids, Biotechnology, Central nervous system depressants, Stem cell transplantation, General interest, News, opinion and commentary, Darzalex (Medication)
Abstract

DENMARK: Genmab A/S has issued the following press release: Genmab A/S (Nasdaq: GMAB) announced today that the U.S. Food and Drug Administration (U.S. FDA) has approved the use of DARZALEX(r) [...]

Published
2019

49. Janssen Announces U.S. FDA Approval of DARZALEX(r) (daratumumab) Combination Regimen for Newly Diagnosed, Transplant-Eligible Patients with Multiple Myeloma

Subjects
United States. Food and Drug Administration, Johnson & Johnson, Multiple myeloma, Daratumumab, Pharmaceutical industry, Drug approval, Stem cell transplantation, Stem cells, Dexamethasone, Glucocorticoids, Bortezomib, General interest, News, opinion and commentary, Darzalex (Medication)
Abstract

HORSHAM: Janssen Pharmaceutical Companies of Johnson & Johnson has issued the following press release: - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug [...]

Published
2019

50. Amgen Announces Phase 3 CANDOR Study Combining KYPROLIS(r) (carfilzomib) And DARZALEX(r) (daratumumab) Meets Primary Endpoint Of Progression-Free Survival

Subjects
Carfilzomib, Multiple myeloma -- Care and treatment, Daratumumab, Death, Recurrence (Disease), Dexamethasone, Glucocorticoids, General interest, News, opinion and commentary, Darzalex (Medication)
Abstract

THOUSAND OAKS: Amgen has issued the following press release: Amgen (NASDAQ:AMGN) today announced the Phase 3 CANDOR study evaluating KYPROLIS(r) (carfilzomib) in combination with dexamethasone and DARZALEX(r) (daratumumab) (KdD) compared [...]

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results